132 related articles for article (PubMed ID: 15210759)
1. A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors.
Xu YM; Wang LF; Jia LT; Qiu XC; Zhao J; Yu CJ; Zhang R; Zhu F; Wang CJ; Jin BQ; Chen SY; Yang AG
J Immunol; 2004 Jul; 173(1):61-7. PubMed ID: 15210759
[TBL] [Abstract][Full Text] [Related]
2. A novel recombinant immunocasp-6 fusion gene specifically and efficiently suppresses HER2-overexpressing osteosarcoma.
Zhou BG; Liu MY; Qiu XC; Xu YM; Fan QY; Yang AG; Zhang Y; Xia H
Oncol Rep; 2013 Jan; 29(1):276-82. PubMed ID: 23135254
[TBL] [Abstract][Full Text] [Related]
3. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3.
Jia LT; Zhang LH; Yu CJ; Zhao J; Xu YM; Gui JH; Jin M; Ji ZL; Wen WH; Wang CJ; Chen SY; Yang AG
Cancer Res; 2003 Jun; 63(12):3257-62. PubMed ID: 12810656
[TBL] [Abstract][Full Text] [Related]
4. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.
Wang LF; Zhou Y; Xu YM; Qiu XC; Zhou BG; Wang F; Long H; Chen X; Yang TT; Ma BA; Fan QY; Yang AG
Cancer Invest; 2009 Aug; 27(7):774-80. PubMed ID: 19488908
[TBL] [Abstract][Full Text] [Related]
5. Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumor growth.
Qiu XC; Xu YM; Wang F; Fan QY; Wang LF; Ma BA; Jia LT; Zhao J; Meng YL; Yao LB; Chen SY; Yang AG
Mol Cancer Ther; 2008 Jul; 7(7):1890-9. PubMed ID: 18644999
[TBL] [Abstract][Full Text] [Related]
6. Selective proapoptotic activity of a secreted recombinant antibody/AIF fusion protein in carcinomas overexpressing HER2.
Yu CJ; Jia LT; Meng YL; Zhao J; Zhang Y; Qiu XC; Xu YM; Wen WH; Yao LB; Fan DM; Jin BQ; Chen SY; Yang AG
Gene Ther; 2006 Feb; 13(4):313-20. PubMed ID: 16267568
[TBL] [Abstract][Full Text] [Related]
7. Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells.
Zhao J; Zhang LH; Jia LT; Zhang L; Xu YM; Wang Z; Yu CJ; Peng WD; Wen WH; Wang CJ; Chen SY; Yang AG
J Biol Chem; 2004 May; 279(20):21343-8. PubMed ID: 15004021
[TBL] [Abstract][Full Text] [Related]
8. [Pro-apoptotic effect on osteosarcoma SOSP-9607 cells by human recombinant caspase-6 fusion protein].
Zhou BG; Qiu XC; Xu YM; Fan QY
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):497-500. PubMed ID: 21029691
[TBL] [Abstract][Full Text] [Related]
9. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.
Guo R; Cao L; Guo W; Liu H; Xu H; Fang Q; Hong Z
Biochem Biophys Res Commun; 2016 Jun; 475(1):93-9. PubMed ID: 27178207
[TBL] [Abstract][Full Text] [Related]
10. Biotechnological and gene therapeutic strategies in cancer treatment.
Wels W; Moritz D; Schmidt M; Jeschke M; Hynes NE; Groner B
Gene; 1995 Jun; 159(1):73-80. PubMed ID: 7607575
[TBL] [Abstract][Full Text] [Related]
11. HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors.
Zielinski R; Lyakhov I; Hassan M; Kuban M; Shafer-Weaver K; Gandjbakhche A; Capala J
Clin Cancer Res; 2011 Aug; 17(15):5071-81. PubMed ID: 21791637
[TBL] [Abstract][Full Text] [Related]
12. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.
Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S
J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808
[TBL] [Abstract][Full Text] [Related]
13. The effect of direct translocation across endosomes on the cytotoxicity of the recombinant protein e23sFv-Fdt-casp6 to HER2 positive gastric cancer cells.
Ren JL; Meng YL; Hu B; Jia LT; Zhang R; Xu YM; Xie QS; Zhang YQ; Jin BQ; Chen SY; Wang T; Yang AG
Biomaterials; 2011 Oct; 32(30):7641-50. PubMed ID: 21767874
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
[TBL] [Abstract][Full Text] [Related]
15. Turn a diarrhoea toxin into a receptor-mediated therapy for a plethora of CLDN-4-overexpressing cancers.
Yao Q; Cao S; Li C; Mengesha A; Low P; Kong B; Dai S; Wei M
Biochem Biophys Res Commun; 2010 Jul; 398(3):413-9. PubMed ID: 20599713
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
Schmidt M; Wels W
Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
[TBL] [Abstract][Full Text] [Related]
17. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein.
Zhang DX; Zhao PT; Xia L; Liu LL; Liang J; Zhai HH; Zhang HB; Guo XG; Wu KC; Xu YM; Jia LT; Yang AG; Chen SY; Fan DM
Gut; 2010 Mar; 59(3):292-9. PubMed ID: 19951902
[TBL] [Abstract][Full Text] [Related]
18. [Targeted tumor suppression by a secreted fusion protein consisting of anti- erbB2 antibody and reversed caspase-3 to SKBr3 cells].
Zhang LH; Jia LT; Yu CJ; Qu P; Dong HL; Zhao J; Xu YM; Wang CJ; Yang AG
Zhonghua Yi Xue Za Zhi; 2003 Apr; 83(7):564-8. PubMed ID: 12887745
[TBL] [Abstract][Full Text] [Related]
19. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.
Simon N; Antignani A; Sarnovsky R; Hewitt SM; FitzGerald D
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075852
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer.
Fischer A; Wolf I; Fuchs H; Masilamani AP; Wolf P
Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33260619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
